广泛期小细胞肺癌患者接受一线免疫联合化疗时胸部放疗的疗效与安全性:倾向性评分匹配的多中心回顾性分析
该多中心回顾性分析纳入2018至2022年间在三家医院接受4至6周期免疫检查点抑制剂联合化疗的广泛期小细胞肺癌患者,按是否接受胸部放疗分组并行倾向性评分匹配。匹配后197例分析显示,胸部放疗组中位无进展生存期10.76个月对7.63个月(P=0.014),中位总生存期21.67个月对16.6个月(P=0.009),且未显著增加不良事件。
要点
- 匹配后胸部放疗组中位无进展生存期10.76个月,非放疗组7.63个月(P=0.014)。
- 匹配后胸部放疗组中位总生存期21.67个月,非放疗组16.6个月(P=0.009)。
- 胸部放疗未显著增加任何级别不良事件(P=0.874)及3-4级不良事件(P=0.909)。
核心结论
- 在接受铂类-依托泊苷化疗联合免疫检查点抑制剂的广泛期小细胞肺癌患者中,加用胸部放疗显示出显著生存获益且耐受性良好,可能是可行的一线治疗策略。
研究设计与样本
- 多中心回顾性分析,纳入2018至2022年间在三家医院接受4至6周期免疫检查点抑制剂联合化疗作为一线治疗的广泛期小细胞肺癌患者。
- 按是否接受胸部放疗分为两组,并进行倾向性评分匹配以使两组特征均衡。
- 主要终点为总生存期和无进展生存期,次要终点为毒性反应。
主要发现
- 共纳入276例患者,中位随访时间22.3个月(范围4.0-53.73个月)。
- 倾向性评分匹配后197例患者进一步分析,其中99例接受胸部放疗。
- 匹配后胸部放疗组与非放疗组中位无进展生存期分别为10.76个月和7.63个月(P=0.014)。
- 匹配后胸部放疗组与非放疗组中位总生存期分别为21.67个月和16.6个月(P=0.009)。
- 胸部放疗是接受免疫检查点抑制剂联合化疗的广泛期小细胞肺癌患者无进展生存期和总生存期的独立预后因素。
关键数值与推荐
- 安全性方面,接受胸部放疗的患者任何级别不良事件(P=0.874)和3-4级不良事件(P=0.909)均未见显著增加。
- 胸部放疗组最常见的不良事件为放射性食管炎、胃肠道毒性和血液学毒性,均可耐受。
- 高剂量放疗与更高的肺炎发生率相关。
临床怎么用
- 原文结论认为,对于接受铂类-依托泊苷化疗联合免疫检查点抑制剂的广泛期小细胞肺癌患者,加用胸部放疗显示出显著生存获益且耐受性良好,可能是可行的一线治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Platinum-etoposide chemotherapy combined with immune checkpoint inhibitors (ICIs) has been recommended as the first-line standard treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, the effect of thoracic radiotherapy (TRT) on these patients is still unknown. This study aimed to evaluate the efficacy and safety of TRT for ES-SCLC patients who responded to first-line ICIs and chemotherapy (CHT). METHODS: Patients who received 4 to 6 cycles of ICIs and CHT as first-line therapy at three hospitals between 2018 and 2022 were included in the analysis. All patients were divided into two groups based on whether they received TRT as first-line treatment, and propensity score matching (PSM) was performed to ensure that the characteristics of two groups were well-balanced. The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoint was toxic effects. RESULTS: A total of 276 patients were included, and the median follow-up time was 22.3 (range, 4.0-53.73) months. After PSM, 197 patients were further analysed, and 99 of whom received TRT. The baseline characteristics were well-balanced between patients in the TRT and non-TRT groups. There were significant differences in PFS between the TRT and non-TRT groups, with the median PFS of 10.76 and 7.63 months, respectively (P = 0.014). Significantly improved OS was observed in the TRT group (21.67 vs. 16.6 months, P = 0.009). In addition, the use of TRT was an independent prognostic factor for PFS and OS of ES-SCLC patients receiving ICIs plus CHT. In terms of safety, no significant increase of any grades adverse event (AE) (P = 0.874) and G3-4 AE (P = 0.909) was observed for patients receiving TRT. Radiation esophagitis, gastrointestinal and hematologic toxicities were the most common AEs in TRT group, which were tolerable. And high-dose radiotherapy was associated with higher incidence of pneumonitis. CONCLUSION: Addition of TRT showed significant survival benefits and well tolerability in ES-SCLC patients receiving platinum-etoposide CHT and ICIs, which could be a feasible first-line treatment strategy for ES-SCLC patients.
引用
- Yao Y, Li B, Song R, et al. Efficacy and safety of thoracic radiotherapy in extensive-stage small-cell lung cancer patients receiving first-line immunotherapy plus chemotherapy: a propensity score matched multicentre retrospective analysis. Radiat Oncol. 2024. PMID: 38413988. doi:10.1186/s13014-024-02420-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。